Literature DB >> 20480217

Mitochondrial matters of the brain: the role in Huntington's disease.

C Turner1, A H V Schapira.   

Abstract

Even before the discovery of the mutant htt gene as the cause of Huntington's Disease (HD), abnormal energy metabolism and mitochondrial dysfunction had been suggested as a possible pathogenic mechanism in HD. These initial investigations described defects in energy metabolism using Positron Emission Tomography (PET) and Nuclear Magnetic Resonance (NMR) Spectroscopy in symptomatic and pre-symptomatic HD patients. Concurrently, 3-nitroproprionic acid, a mitochondrial complex II inhibitor, was found to replicate many of the pathological and clinical features of HD when administered to animals. Subsequently, reductions in mitochondrial respiratory chain enzyme activities in HD brain and muscle, HD mice models and cellular HD models were discovered and confirmed impaired mitochondrial function as an important component of pathogenesis. A unifying hypothesis linking chronic ATP depletion, oxidative stress and mitochondrial dysfunction culminated in the "slow excitotoxic theory" of HD pathogenesis. More recently, the localization of mutant htt within mitochondria and the association between transcriptional dysregulation caused by impaired PGC-1 alpha activity with abnormal mitochondrial biogenesis and function has provided further links with additional potential pathogenic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20480217     DOI: 10.1007/s10863-010-9290-y

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   2.945


  72 in total

Review 1.  NMDA receptor subunits: diversity, development and disease.

Authors:  S Cull-Candy; S Brickley; M Farrant
Journal:  Curr Opin Neurobiol       Date:  2001-06       Impact factor: 6.627

2.  A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease.

Authors:  S T Grafton; J C Mazziotta; J J Pahl; P St George-Hyslop; J L Haines; J Gusella; J M Hoffman; L R Baxter; M E Phelps
Journal:  Ann Neurol       Date:  1990-11       Impact factor: 10.422

3.  Biochemical abnormalities and excitotoxicity in Huntington's disease brain.

Authors:  S J Tabrizi; M W Cleeter; J Xuereb; J W Taanman; J M Cooper; A H Schapira
Journal:  Ann Neurol       Date:  1999-01       Impact factor: 10.422

4.  1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers.

Authors:  B G Jenkins; H D Rosas; Y C Chen; T Makabe; R Myers; M MacDonald; B R Rosen; M F Beal; W J Koroshetz
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

5.  Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy.

Authors:  R Lodi; A H Schapira; D Manners; P Styles; N W Wood; D J Taylor; T T Warner
Journal:  Ann Neurol       Date:  2000-07       Impact factor: 10.422

6.  Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin.

Authors:  Alexandra Benchoua; Yaël Trioulier; Diana Zala; Marie-Claude Gaillard; Nathalie Lefort; Noelle Dufour; Frederic Saudou; Jean-Marc Elalouf; Etienne Hirsch; Philippe Hantraye; Nicole Déglon; Emmanuel Brouillet
Journal:  Mol Biol Cell       Date:  2006-02-01       Impact factor: 4.138

7.  Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates.

Authors:  Hirokazu Fukui; Carlos T Moraes
Journal:  Hum Mol Genet       Date:  2007-03-13       Impact factor: 6.150

8.  Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate.

Authors:  M F Beal; D R Henshaw; B G Jenkins; B R Rosen; J B Schulz
Journal:  Ann Neurol       Date:  1994-12       Impact factor: 10.422

9.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Authors:  Alexander V Panov; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden; James R Burke; Warren J Strittmatter; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2002-08       Impact factor: 24.884

10.  Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons.

Authors:  Diane T W Chang; Gordon L Rintoul; Sruthi Pandipati; Ian J Reynolds
Journal:  Neurobiol Dis       Date:  2006-02-09       Impact factor: 5.996

View more
  14 in total

1.  Targeting sirtuin-1 in Huntington's disease: rationale and current status.

Authors:  Wenzhen Duan
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

2.  Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime.

Authors:  Janett Eckmann; Laura E Clemens; Schamim H Eckert; Stephanie Hagl; Libo Yu-Taeger; Thierry Bordet; Rebecca M Pruss; Walter E Muller; Kristina Leuner; Huu P Nguyen; Gunter P Eckert
Journal:  Mol Neurobiol       Date:  2014-03-18       Impact factor: 5.590

3.  Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage.

Authors:  Ulziibat Shirendeb; Arubala P Reddy; Maria Manczak; Marcus J Calkins; Peizhong Mao; Danilo A Tagle; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2011-01-21       Impact factor: 6.150

Review 4.  Impaired mitochondrial function in psychiatric disorders.

Authors:  Husseini Manji; Tadafumi Kato; Nicholas A Di Prospero; Seth Ness; M Flint Beal; Michael Krams; Guang Chen
Journal:  Nat Rev Neurosci       Date:  2012-04-18       Impact factor: 34.870

5.  Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets.

Authors:  Mali Jiang; Jiawei Wang; Jinrong Fu; Lin Du; Hyunkyung Jeong; Tim West; Lan Xiang; Qi Peng; Zhipeng Hou; Huan Cai; Tamara Seredenina; Nicolas Arbez; Shanshan Zhu; Katherine Sommers; Jennifer Qian; Jiangyang Zhang; Susumu Mori; X William Yang; Kellie L K Tamashiro; Susan Aja; Timothy H Moran; Ruth Luthi-Carter; Bronwen Martin; Stuart Maudsley; Mark P Mattson; Robert H Cichewicz; Christopher A Ross; David M Holtzman; Dimitri Krainc; Wenzhen Duan
Journal:  Nat Med       Date:  2011-12-18       Impact factor: 53.440

6.  Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.

Authors:  Jing Jin; Jennifer Albertz; Zhihong Guo; Qi Peng; Gay Rudow; Juan C Troncoso; Christopher A Ross; Wenzhen Duan
Journal:  J Neurochem       Date:  2013-03-05       Impact factor: 5.372

Review 7.  Primary cultures of astrocytes: their value in understanding astrocytes in health and disease.

Authors:  Sofie C Lange; Lasse K Bak; Helle S Waagepetersen; Arne Schousboe; Michael D Norenberg
Journal:  Neurochem Res       Date:  2012-08-28       Impact factor: 3.996

8.  Altered Ca(2+) signaling in skeletal muscle fibers of the R6/2 mouse, a model of Huntington's disease.

Authors:  Peter Braubach; Murat Orynbayev; Zoita Andronache; Tanja Hering; Georg Bernhard Landwehrmeyer; Katrin S Lindenberg; Werner Melzer
Journal:  J Gen Physiol       Date:  2014-11       Impact factor: 4.086

9.  SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation.

Authors:  Jacqueline Gire O'Rourke; Jaclyn R Gareau; Joseph Ochaba; Wan Song; Tamás Raskó; David Reverter; John Lee; Alex Mas Monteys; Judit Pallos; Lisa Mee; Malini Vashishtha; Barbara L Apostol; Thomas Peter Nicholson; Katalin Illes; Ya-Zhen Zhu; Mary Dasso; Gillian P Bates; Marian Difiglia; Beverly Davidson; Erich E Wanker; J Lawrence Marsh; Christopher D Lima; Joan S Steffan; Leslie M Thompson
Journal:  Cell Rep       Date:  2013-07-18       Impact factor: 9.423

10.  Enhanced neuronal glucose transporter expression reveals metabolic choice in a HD Drosophila model.

Authors:  Marie Thérèse Besson; Karin Alegría; Pamela Garrido-Gerter; Luis Felipe Barros; Jean-Charles Liévens
Journal:  PLoS One       Date:  2015-03-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.